On Amendments To Drug Rules

The Government of India has amended the New Drugs and Clinical Trials Rules, 2019 to reduce regulatory bottlenecks in pharmaceutical research and development, in line with the objective of enhancing ease of doing business.

• By amending the New Drugs and Clinical Trials (NDCT) Rules, 2019, the government aims to catalyze domestic R&D, moving India from being a “volume-driven” manufacturer to an “innovation-led” global leader.

Core Regulatory Shift- From Licensing to Intimation

The Central Drugs Standard Control Organisation (CDSCO) has replaced mandatory manufacturing licenses for research with a paperless system.

• Prior-Intimation Mechanism: Developers can now manufacture small quantities of drugs for research, testing, and analysis simply by filing a “Notice of Intent” on the SUGAM Portal.
• Immediate Action: Once the online acknowledgment is received, companies can begin synthesis without waiting for physical approvals.
• BA/BE Studies: Single-dose, low-risk Bioavailability and Bioequivalence (BA/BE) studies can now commence via the same intimation route, particularly aiding the generic drug industry.

Impact on Ease of Doing Business (EoDB)

• Timeline Reduction: The reform is expected to shave at least 90 days (3 months) off the drug development lifecycle.
• Efficiency for High-Risk Drugs: For categories where licenses are still mandatory (e.g., cytotoxic, narcotic, or psychotropic drugs), processing times have been slashed from 90 days to 45 days.
• Resource Optimization: By automating low-risk approvals, CDSCO (which handles ~35,000 such applications annually) can redirect manpower toward high-risk oversight and quality audits.

Challenges that need to be Tackled

• Quality Assurance Gap: Rapid commencement of research must not lead to a dilution of Good Manufacturing Practices (GMP).
• Surveillance Deficit: Shifting to a “post-facto” check mechanism requires a robust pharmacovigilance system that India is still strengthening.
• Global Credibility Risks: Recent international scandals involving contaminated Indian-made syrups highlight that speed can be fatal if oversight remains fragmented between Central and State authorities.
• Data Integrity: Ensuring that manufacturers maintain “meticulous documentation” as required by the new rules is difficult without frequent, unannounced digital audits.

Way Forward

• Unified Regulatory Authority: Moving toward a “One Nation, One Regulator” model to synchronize standards across all states and eliminate jurisdictional confusion.
• Risk-Based Inspections: Implementing an AI-driven, risk-based inspection frequency where companies with a history of compliance face fewer hurdles, while high-risk entities face stricter scrutiny.
• Strengthening Post-Market Surveillance: Replicating the robust US FDA or EMA models for reporting adverse drug reactions and ensuring mandatory recall laws are enacted.
• Digital Transparency: Making all compliance history and “Notice of Intent” filings publicly accessible to build global trust.

Check Out UPSC CSE Books

Visit PW Store

Conclusion

The 2026 amendments reflect the Jan Vishwas trust-based approach, easing regulatory burdens to spur innovation. However, India’s ambition to be the Pharmacy of the World hinges on matching regulatory agility with strict pharmaceutical quality and patient safety.